KEVEYIS was shown to reduce the number, duration, and severity of attacks of Primary Periodic Paralysis.1
Results in Study 1: Hypokalemic patients treated with KEVEYIS had 2.2 fewer attacks per week than patients treated with placebo. Hyperkalemic patients treated with KEVEYIS had 3.9 fewer attacks per week than patients treated with placebo.2
Results in Study 2: Hyperkalemic patients treated with KEVEYIS had 2.3 fewer attacks per week than patients treated with placebo. For hypokalemic patients, the primary endpoint was the occurrence of an intolerable increase in attack frequency or severity, necessitating withdrawal from the treatment phase. Out of 15 patients, the majority reached acute worsening in the placebo phase.3
The most common adverse reactions in patients treated with KEVEYIS, with incidence ≥10% and rates greater than placebo, were paresthesia, cognitive disorder, dysgeusia, and confusional state.1
KEVEYIS is a 50-mg tablet with twice-daily dosing and the ability to adjust the dose based on individual patient response, which should be evaluated after 2 months of treatment.1
If you are a patient or healthcare provider with questions about how to fill a prescription for KEVEYIS, or if you have any other questions related to KEVEYIS, call 844-KEVEYIS (538-3947) or fax to 844-KEV-1030 (538-1030).
What is KEVEYIS?
KEVEYIS (keh-VAY-iss) (dichlorphenamide) is a prescription drug used to treat primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and other similar diseases.
What should you tell your healthcare provider before taking KEVEYIS?
Tell your doctor if you are allergic to dichlorphenamide or other sulfa drugs; if you take high doses of aspirin, or if you have lung or liver disease; if you are pregnant, plan to become pregnant, or are breastfeeding or plan to breastfeed.
What should you know about KEVEYIS?
What are the most common side effects with KEVEYIS?
The most common side effects are a feeling of numbness, tingling or burning (“pins and needles”) in the toes, feet, hands or fingers; trouble with memory or thinking; feeling confused; and unpleasant taste in the mouth.
These are not all of the possible side effects of KEVEYIS. Call your healthcare provider for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch/ or call 1-800-FDA-1088.
© 2018 Strongbridge Biopharma plc
STRONGBRIDGE BIOPHARMA® is a registered trademark of the Strongbridge Biopharma plc. companies, which include Strongbridge Ireland Limited and Strongbridge U.S. Inc.
KEVEYIS® is a registered trademark licensed exclusively in the U.S. to Strongbridge Biopharma plc.
Macrilen™ is a trademark of Aeterna Zentaris GmbH, licensed exclusively in the U.S. and Canada to Strongbridge Ireland Limited.
MLR-0010 V13 01/2018